H2SITE
29.4.2024 08:31:28 CEST | Business Wire | Press release
Ammonia cracking is gaining momentum as a potential hydrogen carrier for onboard applications and this system is based on H2SITE’s hydrogen-selective membranes that overcome the thermodynamic limitations of the ammonia cracking reaction by recovering hydrogen continuously and resulting in virtually complete ammonia conversion and higher efficiencies at lower temperatures, reducing overall energy consumption and footprint.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240428422597/en/
(Photo: Business Wire)
In awarding the AIP, the design and arrangement evaluation included an overall examination of fundamental aspects of the design and compliance with LR’s Rules and Regulations for the Classification of Ships using Gases or other Low-flashpoint Fuels. A preliminary appraisal of rules was undertaken, followed by a risk assessment conducted to ensure that the risks arising from the use of ammonia and hydrogen are addressed according to LR’s ShipRight Procedure for Risk-Based Certification (RBC).
H2SITE operationally demonstrated its ammonia to hydrogen power technology last November when the Zumaia Offshore’s Bertha B vessel carried onboard AMMONIA to H2POWER technology, validating its performance in actual offshore conditions.
"We are proud to have achieved this milestone, as it validates the design and safety of our onboard ammonia cracking technology for decarbonizing maritime applications based on membrane reactors. Having commissioned our first cracker and fuel cell unit last year aboard the supply vessel Bertha B, we are currently scaling up the technology and designing MW-scale units." according to Jose Medrano Technical Director at H2SITE.
These AMMONIA to H2POWER systems will be integrated with both propulsion systems and auxiliary power units to serve a range of vessels, from offshore platforms to tankers and gas carriers.
Mark Darley, Chief Operations Officer, Lloyd’s Register added: “H2SITE's AMMONIA to H2POWER technology represents an exciting opportunity for shipowners to convert ammonia, and other feedstocks such as methanol, to hydrogen onboard their vessels without using additional gas separation technology”.
“We are pleased to award the AiP for this novel solution, and we remain dedicated to working with the maritime value chain to provide zero-emission power solutions that can contribute towards a greener, more sustainable future.”
About H2SITE
H2SITE was created in 2020 and has an exclusive technology of reactors and separators for the conversion of different feedstocks into hydrogen, among which are ammonia, methanol, or synthetic gas, in addition to the separation of hydrogen from gaseous mixtures in low concentration for applications in salt caverns or geologic hydrogen.
About Lloyd’s Register
Trusted maritime advisers, partnering with clients to drive performance across the ocean economy. Lloyd’s Register (LR) is a global professional services group specialising in marine engineering and technology. With a heritage going back more than 260 years to the establishment of the world’s first marine classification society, LR is dedicated to setting and improving standards for the safety of ships.
Today we are a leading provider of classification and compliance services to the marine and offshore industries, helping our clients design, construct and operate their assets to accepted levels of safety and environmental compliance. We also provide advice, support and solutions on fleet performance, fleet optimisation and voyage optimisation, enhancing our clients’ digital capabilities. Our digital solutions are relied upon by more than 20,000 vessels.
In the race to zero emissions, our research, technical expertise and industry-firsts are supporting a safe, sustainable maritime energy transition.
Lloyd’s Register Group is wholly owned by the Lloyd’s Register Foundation, a politically and financially independent global charity that promotes safety and education.
Find out more lr.org
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240428422597/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Enhertu® Approved in the EU as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer27.10.2026 08:30:00 CET | Press release
Approval based on DESTINY-Breast05 phase 3 trial results that showed Daiichi Sankyo and AstraZeneca’s Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 First EU approval of Enhertu in the curative-intent early breast cancer setting Third approval for Enhertu in the EU in four months Enhertu® (trastuzumab deruxtecan) has been approved in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive (immunohistochemistry [IHC] 3+ or in-situ hybridization [ISH]+) breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for
Avanzanite Bioscience Expands UK Presence and Appoints Sarah O’Connell as Country Manager27.10.2026 08:00:00 CET | Press release
Avanzanite Bioscience B.V., a European pharmaceutical company focused on rare diseases, today announced the expansion of its United Kingdom (UK) presence and the appointment of Sarah O’Connell as UK Country Manager. The move strengthens Avanzanite’s long-term commitment to the UK and its ability to help eligible patients access innovative rare disease medicines. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261027035012/en/ Sarah O'Connell, Country Manager, UK, Avanzanite Bioscience “The UK is essential to our ambition of building Avanzanite into a European rare disease champion. We feel a deep and lasting connection to this market and there is no European reach without the UK,” said Adam Plich, co-founder and CEO, Avanzanite Bioscience. “At a time when parts of the life sciences sector are reassessing their investment and presence in the UK, we are choosing to commit and build for the long term. With Sarah’s extensive rare
LTM Secures Strategic Engagement with a Global Banking and Financial Services Firm27.10.2026 05:30:00 CET | Press release
LTM, the Business Creativity partner to the world's largest enterprises, has secured a strategic engagement with a large global banking and financial services firm, further strengthening its position as a trusted technology and transformation partner to leading financial institutions. This two-year engagement is already underway with an option to extend for an additional year and has a potential value of up to USD 100 million. The engagement reflects the continued expansion of LTM’s relationship with the client and its growing role in advancing strategic technology programmes and supporting supplier consolidation initiatives across the organization. Under the agreement, LTM will serve as a preferred partner driving the consolidation and delivery of strategic technology requirements across key wealth, personal banking, and global functions. The engagement will leverage LTM’s deep banking-domain expertise, engineering excellence, and global delivery capabilities to support the client’s t
DDN Selected to Modernize Research Data Infrastructure at UNSW Sydney26.10.2026 22:30:00 CET | Press release
DDN EXAScaler and Arcitecta Mediaflux will replace 11 legacy storage systems, simplifying access to research data while balancing performance and cost DDN, the global leader in AI and data intelligence solutions, today announced that UNSW Sydney has selected DDN to deliver a new research data storage environment as part of the university’s Research Data Experience (RDE) program. Working with Australian software company Arcitecta, DDN will combine its EXAScaler parallel file system with Arcitecta’s Mediaflux® data management platform to help researchers spend less time managing data and more time using it. Following an extensive 18-month evaluation, UNSW selected an integrated approach that will replace 11 legacy storage systems with a coordinated environment for high-performance storage and enterprise data management. The decision reflects a broader challenge facing research-intensive institutions: how to support rapidly expanding scientific datasets while simplifying infrastructure, i
Agent Assurance by TestMu AI Is Now Generally Available, Letting Teams Test What Their AI Agents Actually Change26.10.2026 16:15:00 CET | Press release
The trial includes 4,000 credits and four concurrent runs, so a team can generate functional and adversarial suites from its own agent's docs and endpoint, with code optional, and gate CI on evidence-backed verdicts without booking a demo. TestMu AI (formerly LambdaTest), the world's first Agentic AI-powered Quality Engineering platform, today announced the general availability of Agent Assurance. Agent Assurance tests AI agents that take actions, such as calling tools, writing files, and changing records, by checking what a run actually changed rather than what the agent says it did. Any team can now create a TestMu AI account and run it against its own agent without booking a demo first. Agent Assurance launched on August 17, 2026, behind a waitlist and a guided onboarding session. Since then, Rook, the CLI that runs Agent Assurance, has shipped a steady run of releases, shaped by feedback from early teams. Agent evaluation has mostly graded the final reply, and that reply can be wro
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
